An Open-label, Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A2009 for Injection in Patients With Advanced Solid Tumors
Latest Information Update: 01 Jan 2025
At a glance
- Drugs SHR-A2009 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Suzhou Suncadia Biopharmaceuticals
Most Recent Events
- 27 Dec 2024 Status changed from active, no longer recruiting to completed.
- 12 Oct 2023 Status changed from recruiting to active, no longer recruiting.
- 20 Oct 2022 Status changed from not yet recruiting to recruiting.